|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **ID** | **Time to relapse,****yrs** | **Age at relapse,****yrs** | **Contra-lateral biopsy¤** | **AFP** **Primary/** **Relapse** | **hCG** **Primary/** **Relapse** | **histology****Primary/**  **Relapse** | **Relapse-stage** | **Treatment** | **Post-****treatment****surgery** | **2nd****Relapse** | **Status** | **Cause of death** |
| **250** | 9.5 | 56 | No CIS | - / - | - / 24 | S / S | IIc | BEP | Necrosis | - | NED |  |
| **369** | 14.3 | 45 | No CIS | - / - | - / - | S / S | IIc | BEP | Necrosis | - | NED |  |
| **476** | 9.7 | 51 | No CIS | - / - | - / 22 | S / S | IIc | BEP | Necrosis | - | NED |  |
| **1076** | 9.3 | 37 | No CIS | - / - | - / 72 | S / No biopsy | IIc | BEP | Necrosis | - | NED |  |
| **2352** | 6.3 | 49 | No CIS | - / - | - / 56 | S / S | IIc | BEP | - | - | NED |  |
| **2687** | 11.4 | 33 | N/A | - / - | 13 / - | S / NS+ T | IIc | BEP | EC +T | Yes | **DoD** | Testicular cancer |
| **2709** | 7.4 | 43 | No CIS | - / - | 260/- | S / N/A\*\* | IIc | BEP | Necrosis | - | NED |  |
| **2719** | 7.2 | 31 | CIS ǂ | - / - | - / 19.8 | S / S | IIc | BEP | - | - | NED |  |
| **3113** | 6.4 | 84 | N/A | - / - | - / - | S / No biopsy | IIb | RT | - | - | NED |  |
| **3728** | 9.8 | 54 | No CIS | - / - | - /116 | S / S | IIc | BEP | - | - | NED |  |
| **4155** | 7.5 | 39 | No CIS | - / - | - /36 | S / S | IIIa | BEP | - | - | NED |  |
| **4163** | 6.6 | 55 | No CIS | - / - | - / - | S / S | IIa | Surgery \* | - | Yes | **DoT** | Pulmonary oedema |
| **4172** | 10.4 | 40 | No CIS | - / - | - /26921 | S / S | IIIa | BEP | - | - | DoC | Angiosarcoma |
| **4576** | 5.4 | 57 | N/A | - /27 | - /- | S / NS | IIc | BEP | - | - | DoC | Lung cancer |
| **4865** | 10.9 | 42 | No CIS | - / - | 60/- | S / S | IIc | BEP | - | - | NED |  |
| **5256** | 7.0 | 38 | N/A | - / - | - / - | S / S | IIIa | BEP | - | - | NED |  |
| **5384** | 6.4 | 29 | N/A | - / - | - / - | S / S | IIc | BEP | - | Yes | **DoD** | Testicular cancer |
| **133** | 8.8 | 43 | No CIS | - / - | - / - | EC/EC | IIIb | BEP | - | - | NED |  |
| **633** | 14.5 | 67 | No CIS | - / - | - / - | S +T / S | IIc | BEP | Necrosis# | - | DoC | Prostate cancer |
| **4091** | 8.8 | 43 | N/A | - / 370 | - / - | S+EC+EST /No biopsy | IIb | BEP | T | - | NED |  |
| **4331** | 25.7 | 52 | No CIS | 4100/ - | 230/ - | S+EC+EST/ NS | IIc | BEP | Fibrosis | - | NED |  |

Table 3: Very late relapses. Patient characteristics at orchiectomy (primary) and at time of relapse. Abbreviations: AFP: alpha fetoprotein, hCG: human chorionic gonadotropin, IGCCCG: International Germ Cell Cancer Collaborative Group, BEP: bleomycin etoposide cisplatin, CIS: carcinoma in situ, N/A: no data available, S: seminoma, NS: nonseminoma, EC: embryonal carcinoma, EST: endodermal sinus tumour, CC: chorionic carcinoma, T: teratoma, NED: no evidence of disease, DoD: dead of disease, DoC: dead of other cancer, DoT: dead of treatment complications. ¤Part of the Danish CIS-screening programme. ǂCIS in contralateral testicle at time of orchiectomy; the patient received radiotherapy (16 GY) for his CIS. \*surgery for local relapse in scrotum; the patient received BEP for his 2nd relapse but died of pulmonary oedema during BEP-treatment. \*\*inconclusive biopsy, # biopsies of residual tumour only.